SUPPLEMENTAL NEW DRUG APPLICATION SUBMITTED TO U.S. FDA FOR CAPLYTA® (LUMATEPERONE) WITH DATA DEMONSTRATING SIGNIFICANT SCHIZOPHRENIA RELAPSE PREVENTION COMPARED TO PLACEBO

Reuters · 07/08 12:00

Please log in to view news